US 11,702,387 B2
Substituted indoline derivatives as dengue viral replication inhibitors
Jean-François Bonfanti, Issy-les-Moulineaux (FR); Bart Rudolf Romanie Kesteleyn, Beerse (BE); Dorothée Alice Marie-Eve Bardiot, Leuven (BE); Arnaud Didier M Marchand, Leuven (BE); Erwin Coesemans, Beerse (BE); Benoît Christian Albert Ghislain De Boeck, Beerse (BE); and Pierre Jean-Marie Bernard Raboisson, Beerse (BE)
Assigned to Janssen Pharmaceuticals, Inc., Titusville, NJ (US); and Katholieke Universiteit Leuven, Leuven (BE)
Filed by Janssen Pharmaceuticals, Inc., Titusville, NJ (US); and Katholieke Universiteit Leuven, Leuven (BE)
Filed on May 28, 2021, as Appl. No. 17/334,432.
Application 17/334,432 is a continuation of application No. 16/614,715, granted, now 11,053,196, previously published as PCT/EP2018/063029, filed on May 18, 2018.
Claims priority of application No. 17172247 (EP), filed on May 22, 2017.
Prior Publication US 2021/0300868 A1, Sep. 30, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 209/04 (2006.01); A61K 45/06 (2006.01); A61P 31/14 (2006.01); C07D 495/04 (2006.01)
CPC C07D 209/04 (2013.01) [A61P 31/14 (2018.01); C07D 495/04 (2013.01); A61K 45/06 (2013.01); C07B 2200/07 (2013.01)] 14 Claims
 
1. A compound of formula (I), or a stereochemically isomeric form thereof,

OG Complex Work Unit Chemistry
wherein
A is

OG Complex Work Unit Chemistry
R1 is fluoro, R2 is methoxy, R3 is hydrogen, R4 is trifluoromethoxy, R5 is hydrogen, Z is carbon, and R6 is hydrogen;
or a pharmaceutically acceptable salt, solvate or polymorph thereof.